Development of a Method That Eliminates False-Positive Results due to Nerve Growth Factor Interference in the Assessment of Fulranumab Immunogenicity

Register
Cart (0)

Home > References > 2014 > Development of a Method That Eliminates False-Positive Results due to Nerve Growth Factor Interference in the Assessment of Fulranumab Immunogenicity

Contact an Account Manager

Development of a Method That Eliminates False-Positive Results due to Nerve Growth Factor Interference in the Assessment of Fulranumab Immunogenicity

Sheng Dai, Allen Schantz, Adrienne Clements-Egan, Michael Cannon, and Gopi Shankar

Journal		AAPS
Species
Analytes Measured
Matrix Tested		Serum

Year		2014
Volume		16
Page Numbers		464-477
Application		Immunogenicity

View Publications

R-PLEX: Matched Antibody Sets - Suitable for Many Research Applications

Quick Links

Browse Our Products

By Analytes

By Applications

Contact Information

Customer Service/Orders
1-240-314-2795

5:00 a.m. to 8:00 p.m.
US Eastern Time

Email

Scientific/Technical Support
1-240-314-2798

8:30 a.m. to 5:30 p.m.
US Eastern Time

Email

Instrument Support
1-301-947-2057

8:30 a.m. - 5:30 p.m.
US Eastern Time

Email

Company Headquarters
1-240-314-2600
1601 Research Blvd.
Rockville, Maryland 20850-3173
USA

Please Sign In

User name

Password

Development of a Method That Eliminates False-Positive Results due to Nerve Growth Factor Interference in the Assessment of Fulranumab Immunogenicity

Abstract

Quick Links

Browse Our Products

Contact Information

Products

Services

Orders & Support

Key Topics